Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations sectio...
Cullinan Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY on Thursday, September 4, 2025, at 2:10 p.m. ET. Nadim Ahmed, Chief Execut...
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D.,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.